open access

Vol 19, No 6 (2014)
Original research articles
Published online: 2014-11-01
Submitted: 2014-01-06
Get Citation

Tolerability and toxicity of prophylactic cranial irradiation in patients with non-small cell lung cancer – Results of a phase II study (with estimation of hematological toxicity, pituitary function and magnetic resonance spectra changes)

Marzena Gawkowska-Suwińska, Sławomir Blamek, Alicja Heyda, Łukasz Boguszewicz, Anna Cichoń, Łukasz Zarudzki, Elżbieta Nowicka, Katarzyna Behrendt, Beata Smolska-Ciszewska, Grzegorz Plewicki, Aleksander Zajusz, Rafał Tarnawski
DOI: 10.1016/j.rpor.2014.05.002
·
Rep Pract Oncol Radiother 2014;19(6):361-368.

open access

Vol 19, No 6 (2014)
Original research articles
Published online: 2014-11-01
Submitted: 2014-01-06

Abstract

Aim

To evaluate the tolerability and toxicity of PCI in patients with NSCLC.

Background

Prophylactic cranial irradiation (PCI) is a standard treatment for patients with small cell lung cancer. There are data showing a decreasing ratio of brain metastases after PCI for non-small cell lung cancer (NSCLC-non small cell lung cancer) patients but, so far, there is no evidence for increasing overall survival. The main concern in this setting is the tolerance and toxicity of the treatment.

Materials and methods

From 1999 to 2007, 50 patients with NSCLC treated with radical intent underwent PCI (30[[ce:hsp sp="0.25"/]]Gy in 15 fractions). Mean follow-up was 2.8 years. The tolerability and hematological toxicity were evaluated in all patients, a part of participants had done neuropsychological tests, magnetic resonance imaging with 1H nuclear magnetic resonance spectra, and estimation of pituitary function.

Results

During follow-up, 20 patients developed distant metastases, 4-brain metastases. Fourteen (30%) patients had acute side effects: (headache, nausea, erythema of the skin). The symptoms did not require treatment breaks. Six patients complained of late side effects (vertigo, nausea, anxiety, lower extremity weakness, deterioration of hearing and olfactory hyperesthesia). Hematological complications were not observed. Testosterone levels tended to decrease (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.062). Visual-motor function deteriorated after treatment (p[[ce:hsp sp="0.25"/]]<[[ce:hsp sp="0.25"/]]0.059). Performance IQ decreased (p[[ce:hsp sp="0.25"/]]<[[ce:hsp sp="0.25"/]]0.025) and the difference between performance IQ and verbal IQ increased (p[[ce:hsp sp="0.25"/]]<[[ce:hsp sp="0.25"/]]0.011). Degenerative periventricular vascular changes were observed in two patients. Analysis of the spectroscopic data showed metabolic but reversible alterations after PCI.

Conclusion

PCI in the current series was well tolerated and associated with a relatively low toxicity.

Abstract

Aim

To evaluate the tolerability and toxicity of PCI in patients with NSCLC.

Background

Prophylactic cranial irradiation (PCI) is a standard treatment for patients with small cell lung cancer. There are data showing a decreasing ratio of brain metastases after PCI for non-small cell lung cancer (NSCLC-non small cell lung cancer) patients but, so far, there is no evidence for increasing overall survival. The main concern in this setting is the tolerance and toxicity of the treatment.

Materials and methods

From 1999 to 2007, 50 patients with NSCLC treated with radical intent underwent PCI (30[[ce:hsp sp="0.25"/]]Gy in 15 fractions). Mean follow-up was 2.8 years. The tolerability and hematological toxicity were evaluated in all patients, a part of participants had done neuropsychological tests, magnetic resonance imaging with 1H nuclear magnetic resonance spectra, and estimation of pituitary function.

Results

During follow-up, 20 patients developed distant metastases, 4-brain metastases. Fourteen (30%) patients had acute side effects: (headache, nausea, erythema of the skin). The symptoms did not require treatment breaks. Six patients complained of late side effects (vertigo, nausea, anxiety, lower extremity weakness, deterioration of hearing and olfactory hyperesthesia). Hematological complications were not observed. Testosterone levels tended to decrease (p[[ce:hsp sp="0.25"/]]=[[ce:hsp sp="0.25"/]]0.062). Visual-motor function deteriorated after treatment (p[[ce:hsp sp="0.25"/]]<[[ce:hsp sp="0.25"/]]0.059). Performance IQ decreased (p[[ce:hsp sp="0.25"/]]<[[ce:hsp sp="0.25"/]]0.025) and the difference between performance IQ and verbal IQ increased (p[[ce:hsp sp="0.25"/]]<[[ce:hsp sp="0.25"/]]0.011). Degenerative periventricular vascular changes were observed in two patients. Analysis of the spectroscopic data showed metabolic but reversible alterations after PCI.

Conclusion

PCI in the current series was well tolerated and associated with a relatively low toxicity.

Get Citation

Keywords

Non-small cell lung cancer (NSCLC); Prophylactic cranial irradiation (PCI); Toxicity of radiotherapy; Testosterone level; MRS – [[ce:sup loc=" pre" ]]1H nuclear magnetic resonance spectra

About this article
Title

Tolerability and toxicity of prophylactic cranial irradiation in patients with non-small cell lung cancer – Results of a phase II study (with estimation of hematological toxicity, pituitary function and magnetic resonance spectra changes)

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 19, No 6 (2014)

Pages

361-368

Published online

2014-11-01

DOI

10.1016/j.rpor.2014.05.002

Bibliographic record

Rep Pract Oncol Radiother 2014;19(6):361-368.

Keywords

Non-small cell lung cancer (NSCLC)
Prophylactic cranial irradiation (PCI)
Toxicity of radiotherapy
Testosterone level
MRS – [[ce:sup loc="pre"]]1H nuclear magnetic resonance spectra

Authors

Marzena Gawkowska-Suwińska
Sławomir Blamek
Alicja Heyda
Łukasz Boguszewicz
Anna Cichoń
Łukasz Zarudzki
Elżbieta Nowicka
Katarzyna Behrendt
Beata Smolska-Ciszewska
Grzegorz Plewicki
Aleksander Zajusz
Rafał Tarnawski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl